A Phase 1 interventional study of PRT064445 and Placebo in Healthy, sponsored by Portola Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-04.
Sponsored by Portola Pharmaceuticals · Phase 1, Interventional, and Other
This is a single center, double-blind, randomized, placebo-controlled, ascending, single dose study of PRT064445 or its matching placebo, in healthy subjects.
Portola Pharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Dose 1 versus Placebo
Biological: PRT064445 · Drug: Placebo
Dose 2 versus Placebo
Biological: PRT064445 · Drug: Placebo
Dose 3 versus Placebo
Biological: PRT064445 · Drug: Placebo
Dose 4 versus Placebo
Biological: PRT064445 · Drug: Placebo
Dose 5 versus Placebo
Biological: PRT064445 · Drug: Placebo
Intravenous
Intravenous to mimic PRT064445
Also known as: Placebo (for PRT064445)
Pharmacodynamics assessments
Time frame: Up to 28 days
Pharmacokinetics: Plasma levels of PRT064445
Time frame: Up to 7 days
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Portola Pharmaceuticals